This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Use of SMS text messaging and videos in bowel cancer screening

Authoring team

In Australia, a study (SMARTscreen) aimed to test whether a multi-intervention short message service (SMS) sent by general practices to 50–60-year-old patients who were due to receive the NBCSP (national bowel cancer screening programme) kit would increase NBCSP uptake, by comparing it with usual care (1):

  • for intervention practices, people due to receive the NBCSP kit within a 6-month study period were sent an SMS just before receiving the kit
    • SMS included a personalised message from the person’s general practice endorsing the kit, a motivational narrative video, an instructional video, and a link to more information
    • control practices continued with usual care, comprising at-home testing with a faecal immunochemical test (FIT) through the NBCSP

  • study results showed that:
    • 39.2% (1143/2914) of people in 11 intervention practices and 23.0% (583/2537) of people in 10 control practices had a FIT result in their electronic health records - a difference of 16.5% (95% confidence interval = 2.02 to 30.9)
    • note that it has been estimated that increasing screening participation by 10% could prevent 27 000 incident CRC diagnoses and 16 800 cancer deaths, and that an additional A$200 million expenditure could be saved over the next 20 years in the Australian population

  • study authors concluded:
    • SMS intervention increased NBCSP kit return in 50–60-year-old patients in general practice

A US study investigated whether providing information on patient risk for advanced colorectal neoplasia (ACN; which includes CRC and advanced precancerous lesions) to patients and providers affects screening uptake, and to identify effect moderators (2):

  • participants were randomly assigned to view a CRC screening decision aid with or without a personalized message about ACN risk. Providers were randomly assigned to receive notifications that the patient was due for screening, with or without a personalized message about the patient’s ACN risk
  • participants - 214 providers and 1084 average-risk patients due for screening
  • study results
    • overall, there were no differences in screening uptake or test completion for the provider notification (predicted probabilities, 41.5% vs. 36.4% for personalized vs. generic; difference, 5.1 [95% CI, −1.6 to 11.8] percentage points) or decision aid (predicted probabilities, 36.8% vs. 41.0% for personalized vs. generic; difference, −4.1 [CI, −10.2 to 1.9] percentage points) interventions
    • health system was an effect moderator for stool testing. For one health system, the stool testing rate was higher for personalized versus generic provider notification (predicted probabilities, 21.1% vs. 7.9%; difference, 13.2 [CI, 1.6 to 24.8] percentage points) when the decision aid was generic
    • the stool testing rate was higher for the personalized versus the generic decision aid (predicted probabilities, 21.4% vs. 7.9%; difference, 13.5 [CI, 2.4 to 24.5] percentage points) when the provider notification was generic
  • the study authors concluded:
    • although including personalized risk for ACN in a decision aid or provider notification had no overall effect, it increased uptake of stool testing in one health system

Reference:

  1. McIntosh JG et al. Increasing bowel cancer screening using SMS in general practice: the SMARTscreen cluster randomised trial. British Journal of General Practice 18 March 2024; BJGP.2023.0230. DOI: https://doi.org/10.3399/BJGP.2023.0230
  2. Schwartz PH et al. et al. Effect of Personalized Risk Messages on Uptake of Colorectal Cancer Screening (https://www.acpjournals.org/doi/abs/10.7326/ANNALS-24-03144): A Randomized Controlled Trial. Ann Intern Med.[Epub 2 September 2025].

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.